Chewing a bagel while reading the morning news, speaking while driving, dislodging a piece of food stuck between two teeth: ...

Onabotulinumtoxin A is under clinical development by AbbVie and currently in Phase III for Unspecified Musculoskeletal Disorders.

Merz Therapeutics, a subsidiary of Merz Pharma GmbH & Co KgaA, focuses on developing and distributing therapeutic solutions for neurological movement disorders, including dystonia, spasticity, and ...